PU.1 and CEBPA expression in acute myeloid leukemia

Francesco D'Alò; Annalisa Di Ruscio; Francesco Guidi; Emiliano Fabiani; Mariangela Greco; Carlo Rumi; Stefan Hohaus; Maria Teresa Voso; Giuseppe Leone

doi:10.1016/j.leukres.2008.01.007

PU.1 and CEBPA expression in acute myeloid leukemia

Francesco D'Alò, Annalisa Di Ruscio, Francesco Guidi, Emiliano Fabiani, Mariangela Greco, Carlo Rumi, Stefan Hohaus, Maria Teresa Voso, Giuseppe Leone

Research output: Contribution to journal › Article › peer-review

Abstract

Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and PU.1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU.1 mRNA levels by real-time RT-PCR in 109 primary AML samples, compared with normal bone marrow and peripheral blood cells. Low PU.1 levels were observed in monoblastic leukemias, while low CEBPA levels were associated with leukopenia at diagnosis and lack of expression of differentiation antigens CD33 and CD11c. We conclude that down-regulation of CEBPA and PU.1 is not a general feature of primary AML, but appears to be restricted to distinct AML subtypes.

Original language	English
Pages (from-to)	1448-1453
Number of pages	6
Journal	Leukemia Research
Volume	32
Issue number	9
DOIs	https://doi.org/10.1016/j.leukres.2008.01.007
Publication status	Published - Sept 2008
Externally published	Yes

Keywords

Acute myeloid leukemia
CEBPA
PU.1
Transcription factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2008.01.007

Cite this

@article{e6c6b57c91a34e7da57f684efb53dc02,

title = "PU.1 and CEBPA expression in acute myeloid leukemia",

abstract = "Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and PU.1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU.1 mRNA levels by real-time RT-PCR in 109 primary AML samples, compared with normal bone marrow and peripheral blood cells. Low PU.1 levels were observed in monoblastic leukemias, while low CEBPA levels were associated with leukopenia at diagnosis and lack of expression of differentiation antigens CD33 and CD11c. We conclude that down-regulation of CEBPA and PU.1 is not a general feature of primary AML, but appears to be restricted to distinct AML subtypes.",

keywords = "Acute myeloid leukemia, CEBPA, PU.1, Transcription factors",

author = "Francesco D'Al{\`o} and \{Di Ruscio\}, Annalisa and Francesco Guidi and Emiliano Fabiani and Mariangela Greco and Carlo Rumi and Stefan Hohaus and Voso, \{Maria Teresa\} and Giuseppe Leone",

note = "Funding Information: The authors would like to thank Daniel G. Tenen for providing oligonucleotide sequences and excellent suggestions, Iolanda Bayer for cytogenetic data, Pierluigi Puggioni for flow cytometry, and all members of the Laboratory of Molecular Biology at the Institute of Hematology of the Catholic University, Rome. This research was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.). ",

year = "2008",

month = sep,

doi = "10.1016/j.leukres.2008.01.007",

language = "English",

volume = "32",

pages = "1448--1453",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "9",

}

TY - JOUR

T1 - PU.1 and CEBPA expression in acute myeloid leukemia

AU - D'Alò, Francesco

AU - Di Ruscio, Annalisa

AU - Guidi, Francesco

AU - Fabiani, Emiliano

AU - Greco, Mariangela

AU - Rumi, Carlo

AU - Hohaus, Stefan

AU - Voso, Maria Teresa

AU - Leone, Giuseppe

N1 - Funding Information: The authors would like to thank Daniel G. Tenen for providing oligonucleotide sequences and excellent suggestions, Iolanda Bayer for cytogenetic data, Pierluigi Puggioni for flow cytometry, and all members of the Laboratory of Molecular Biology at the Institute of Hematology of the Catholic University, Rome. This research was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.).

PY - 2008/9

Y1 - 2008/9

N2 - Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and PU.1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU.1 mRNA levels by real-time RT-PCR in 109 primary AML samples, compared with normal bone marrow and peripheral blood cells. Low PU.1 levels were observed in monoblastic leukemias, while low CEBPA levels were associated with leukopenia at diagnosis and lack of expression of differentiation antigens CD33 and CD11c. We conclude that down-regulation of CEBPA and PU.1 is not a general feature of primary AML, but appears to be restricted to distinct AML subtypes.

AB - Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and PU.1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU.1 mRNA levels by real-time RT-PCR in 109 primary AML samples, compared with normal bone marrow and peripheral blood cells. Low PU.1 levels were observed in monoblastic leukemias, while low CEBPA levels were associated with leukopenia at diagnosis and lack of expression of differentiation antigens CD33 and CD11c. We conclude that down-regulation of CEBPA and PU.1 is not a general feature of primary AML, but appears to be restricted to distinct AML subtypes.

KW - Acute myeloid leukemia

KW - CEBPA

KW - PU.1

KW - Transcription factors

UR - https://www.scopus.com/pages/publications/43049178362

U2 - 10.1016/j.leukres.2008.01.007

DO - 10.1016/j.leukres.2008.01.007

M3 - Article

SN - 0145-2126

VL - 32

SP - 1448

EP - 1453

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

PU.1 and CEBPA expression in acute myeloid leukemia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this